Fawzy Mohamed N, Abd El-Haleim Enas A, Zaki Hala F, Salem Hesham A, El-Sayed Rehab M
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Sinai University- Arish Branch, Arish 45511, Egypt.
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
Life Sci. 2025 Apr 1;366-367:123488. doi: 10.1016/j.lfs.2025.123488. Epub 2025 Feb 19.
Comorbidities with epilepsy and antiseizure medications (ASMs) are currently the main challenges in treating epilepsy. The current study evaluates for the first time the neuroprotective effect of roflumilast (ROF) alone or combined with phenytoin (PHT) against pentylenetetrazol (PTZ)-induced kindling in mice. It focuses on the crosstalk between the NOD-like receptor protein 3 (NLRP3)/caspase 1/interleukin 1β (IL-1β) cascade and the brain-derived neurotrophic factor (BDNF)/sirtuin 3 (SIRT3) pathway as possible strategies to treat epilepsy.
The kindled mouse model was induced via fifteen (35 mg/kg) intraperitoneal injections every other day. Roflumilast (0.4 mg/kg) and phenytoin (30 mg/kg) were orally administered daily from the start until the end of the experiment. Following the PTZ injection, the seizure severity score was assessed. The Morris water maze (MWM) test was performed to evaluate cognition. Histopathological examinations of hippocampi were conducted.
Roflumilast significantly improved neurobehavioral and histological assessments, whereas Racine scores declined. The improvement was confirmed through BDNF upregulation in contrast to NLRP3 and caspase-1 in the hippocampus, as revealed immunohistochemically. In addition, roflumilast induced a prominent elevation in gamma-aminobutyric acid (GABA), sirtuin 3 (SIRT3), and glutathione peroxidase (GPX4), whereas malondialdehyde (MDA), and arachidonic acid 15-lipoxygenase (ALOX15) expressions were downregulated.
Our findings demonstrate that roflumilast conferred neuroprotective benefits against PTZ-induced kindling seizures, suggesting its potential as a novel adjuvant therapy for epilepsy-related disorders. This effect might be due to the modification of the NLRP3 inflammasome/BDNF pathway, ferroptosis, and a decrease in oxidative stress and neuroinflammation.
癫痫合并症和抗癫痫药物(ASMs)是目前癫痫治疗中的主要挑战。本研究首次评估罗氟司特(ROF)单独或与苯妥英(PHT)联合使用对戊四氮(PTZ)诱导的小鼠点燃效应的神经保护作用。研究聚焦于NOD样受体蛋白3(NLRP3)/半胱天冬酶1/白细胞介素1β(IL-1β)级联反应与脑源性神经营养因子(BDNF)/沉默调节蛋白3(SIRT3)通路之间的相互作用,将其作为治疗癫痫的可能策略。
每隔一天通过15次(35毫克/千克)腹腔注射诱导点燃小鼠模型。从实验开始到结束,每天口服罗氟司特(0.4毫克/千克)和苯妥英(30毫克/千克)。注射PTZ后,评估癫痫发作严重程度评分。进行莫里斯水迷宫(MWM)试验以评估认知功能。对海马进行组织病理学检查。
罗氟司特显著改善了神经行为和组织学评估,同时拉辛评分下降。免疫组织化学显示,与海马中的NLRP3和半胱天冬酶-1相比,BDNF上调证实了这种改善。此外,罗氟司特使γ-氨基丁酸(GABA)、沉默调节蛋白3(SIRT3)和谷胱甘肽过氧化物酶(GPX4)显著升高,而丙二醛(MDA)和花生四烯酸15-脂氧合酶(ALOX15)的表达下调。
我们的研究结果表明,罗氟司特对PTZ诱导的点燃性癫痫具有神经保护作用,并提示其作为癫痫相关疾病新型辅助治疗药物的潜力。这种作用可能归因于NLRP3炎性小体/BDNF通路的改变、铁死亡以及氧化应激和神经炎症的减轻。